UMIN-CTR 臨床試験登録情報の閲覧

Recruitment status Terminated
Unique ID issued by UMIN UMIN000042744
Receipt No. R000048789
Scientific Title network meta-analysis of first-line treatment for ALK-positive NSCLC
Date of disclosure of the study information 2020/12/14
Last modified on 2021/12/20 (Ver. 2)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title network meta-analysis of first-line treatment for ALK-positive NSCLC
Acronym NMA of 1L ALK inhibitors
Scientific Title network meta-analysis of first-line treatment for ALK-positive NSCLC
Scientific Title:Acronym NMA of 1L ALK inhibitors
Region
Japan

Condition
Condition ALK-positive NSCLC
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 Aim of this study is to compare first-line treatment for ALK-positive NSCLC.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes OS
Key secondary outcomes PFS, ORR, AE(>g3), TRD

Base
Study type Others,meta-analysis etc

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria English-written individually randomized controlled trials for ALK-positive NSCLC will be included. A trial should have recruited untreated, chemo-naive, or ALK naive patients.
Key exclusion criteria None
Target sample size

Research contact person
Name of lead principal investigator
1st name Nobuyuki
Middle name
Last name Horita
Organization Yokohama City University
Division name Department of Pulmonology
Zip code 236-0004
Address 3-9, Fikuura, Kanazawa, Yokohama, Japan
TEL +81457872800
Email horitano@yokohama-cu.ac.jp

Public contact
Name of contact person
1st name Nobuyuki
Middle name
Last name Horita
Organization Yokohama City University
Division name Department of Pulmonology
Zip code 236-0004
Address 3-9, Fikuura, Kanazawa, Yokohama, Japan
TEL +81457872800
Homepage URL
Email horitano@yokohama-cu.ac.jp

Sponsor
Institute Yokohama City University
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization NA
Address NA
Tel NA
Email NA

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 12 Month 14 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2020 Year 12 Month 14 Day
Date of IRB
2020 Year 12 Month 14 Day
Anticipated trial start date
2020 Year 12 Month 14 Day
Last follow-up date
2021 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information The frequentist weighted least squares approach random-model network meta-analysis will be performed by the R software (Command: netmeta, Package: netmeta). An odds ratio (OR) of a binary outcome should be continuous corrected with 0.5 if necessary. OR and hazard ratio (HR) will be log converted prior to meta-analysis. P value less than 0.05 is considered significant.

Management information
Registered date
2020 Year 12 Month 14 Day
Last modified on
2021 Year 12 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048789